Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Characterization of Epigenetic Gene Silencing in a Subtype of Acute Leukemia Patients with a Poor Prognosis
FY 2009-10
Summary
Acute leukemia is a rapidly progressing disease. It is generally divided into myeloid and lymphoid lineages. Each lineage of acute leukemia is defined by distinct treatment and prognosis. However, a subtype of acute leukemia cases, identified as Cluster 4, exhibit features of both lineages. Thus, Cluster 4 cases are biologically unique and hard to diagnose. Patients belonging to Cluster 4 have a very poor prognosis due to the ineffectiveness of current treatment methods and thus, they are in need of a new therapeutic approach. The repression of tumor suppressor genes characterizes Cluster 4 cases. The repression of these genes is an important determinant of cancer development. I will investigate whether the suppression of these tumor suppressor genes in Cluster 4 cases involves the two major mechanisms of epigenetic silencing: (i) Polycomb Group (PcG) protein recruitment (ii) DNA promoter methylation. My plan of study has three aims: (1) Identification of Cluster 4 Patient Samples: I plan to screen a collection of leukemia patient samples and select the samples that exhibit gene expression levels characteristic of Cluster 4 cases. (2) Identification of PcG Protein Promoter Binding Sites: As the recruitment of PcG proteins to a region of DNA can result gene silencing, I will determine if PcG proteins are recruited to bind DNA. The finding that PcG proteins are atypically recruited to DNA binding sites will lead the way to identifying a protein that acts to nucleate the recruitment of the PcG. (3) Analysis of Promoter Methylation: I aim to examine gene promoter methylation of genes of interest, by isolating DNA from normal blood and bone marrow samples and Cluster 4 samples, and performing an assay that can detect the methylation status of DNA. By comparing the resulting methylation patterns of normal cells with leukemia patient cells, I will be able to determine if promoter methylation contributes to genetic silencing. In summary, by correlating the contributio
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
201064
Name
Sepiashvili Lusia
Region
Ontario
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Characterization of Epigenetic Gene Silencing in a Subtype of Acute Leukemia Patients with a Poor Prognosis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chromatin Immunoprecipitation; Cpg Island Microarray; Dna Methylation; Epigenetics; Leukemia; Polycomb Group Proteins; Reverse Transcription Polymerase Chain Reaction
Abstract
Acute leukemia is a rapidly progressing disease. It is generally divided into myeloid and lymphoid lineages. Each lineage of acute leukemia is defined by distinct treatment and prognosis. However, a subtype of acute leukemia cases, identified as Cluster 4, exhibit features of both lineages. Thus, Cluster 4 cases are biologically unique and hard to diagnose. Patients belonging to Cluster 4 have a very poor prognosis due to the ineffectiveness of current treatment methods and thus, they are in need of a new therapeutic approach. The repression of tumor suppressor genes characterizes Cluster 4 cases. The repression of these genes is an important determinant of cancer development. I will investigate whether the suppression of these tumor suppressor genes in Cluster 4 cases involves the two major mechanisms of epigenetic silencing: (i) Polycomb Group (PcG) protein recruitment (ii) DNA promoter methylation. My plan of study has three aims: (1) Identification of Cluster 4 Patient Samples: I plan to screen a collection of leukemia patient samples and select the samples that exhibit gene expression levels characteristic of Cluster 4 cases. (2) Identification of PcG Protein Promoter Binding Sites: As the recruitment of PcG proteins to a region of DNA can result gene silencing, I will determine if PcG proteins are recruited to bind DNA. The finding that PcG proteins are atypically recruited to DNA binding sites will lead the way to identifying a protein that acts to nucleate the recruitment of the PcG. (3) Analysis of Promoter Methylation: I aim to examine gene promoter methylation of genes of interest, by isolating DNA from normal blood and bone marrow samples and Cluster 4 samples, and performing an assay that can detect the methylation status of DNA. By comparing the resulting methylation patterns of normal cells with leukemia patient cells, I will be able to determine if promoter methylation contributes to genetic silencing. In summary, by correlating the contributio
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sepiashvili, Lusia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~